Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
Palovarotene is the first medicine to be submitted for regulatory approval for FOP.
- Palovarotene is the first medicine to be submitted for regulatory approval for FOP.
- are for managing the symptoms caused by FOP, such as inflammation and chronic pain and not the underlying disease.
- and for the clinicians managing this chronic and progressive disease,” said Dr. Genevieve Baujat, Clinical Geneticist Consultant at Necker-Enfants Malades Hospital, Paris, France.
- “Many of my colleagues and I have been waiting for a long time for a treatment that can help us manage the devastating disease that is FOP.